Using radiofrequency ablation to manage pain in patients with advanced pancreatic cancer
Endoscopic Ultrasound-guided Radiofrequency Ablation of Celiac Ganglion for Pain Management and Improvement of Quality of Life in Patients With Unresectable Pancreatic Cancer
West Virginia University · NCT05535894
This study is testing whether a special treatment called radiofrequency ablation can help manage pain and improve quality of life for people with advanced pancreatic cancer that can't be surgically removed.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 12 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | West Virginia University (other) |
| Locations | 1 site (Morgantown, West Virginia) |
| Trial ID | NCT05535894 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) for managing pain and improving quality of life in patients with unresectable pancreatic cancer. The primary goals include assessing pain control and the reduction of analgesic medication requirements among participants. Patients will be monitored for changes in their pain levels and overall quality of life following the intervention. This observational study aims to provide insights into the utility of EUS-RFA in this challenging patient population.
Who should consider this trial
Good fit: Ideal candidates are patients diagnosed with inoperable pancreatic cancer who experience abdominal or back pain and have not responded to standard analgesic treatments.
Not a fit: Patients with surgically resectable pancreatic cancer or those whose pain is due to causes other than pancreatic malignancy may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve pain management and quality of life for patients suffering from advanced pancreatic cancer.
How similar studies have performed: While there is limited data on EUS-RFA specifically for pancreatic cancer pain management, similar approaches in pain management have shown promise in other contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of pancreatic cancer based on clinical, radiological, or pathological assessment; * Referred for abdominal and/or back pain due to pancreatic cancer; * No prior history of RFA; * Cancer pain unresponsive to the WHO 3-step analgesic ladder; * Willingness to consent to participate in the study. Exclusion Criteria: * Patients who are not willing to give informed consent or agree to participate in the study * Surgically resectable pancreatic cancer; * Abdominal pain with etiology other than pancreatic malignancy; * Evidence of concurrent infection; * Patients with irreversible coagulopathy international normalized ratio \>1.5 or platelet count \<50,000/mm3), * Patients with a preliminary diagnosis of adenocarcinoma are not possible established with intraprocedural at EUS-guided FNA.
Where this trial is running
Morgantown, West Virginia
- Shailendra Singh — Morgantown, West Virginia, United States (RECRUITING)
Study contacts
- Principal investigator: Shailendra Singh, MD — West Virginia University
- Study coordinator: Shailendra Singh, MD
- Email: shailendra.singh@hsc.wvu.edu
- Phone: 3042934123
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pancreatic Cancer